AR Threats Report (CDC)
This report is dedicated to the 48,700 familieswho lose a loved one each year to antibiotic resistanceor Clostridioides difficile, and the...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Look What We Found. A Bavarian Cure for the Common Cold and CoronaVirus Play!
Adding Bavarian Nordic (BVNRY) $10.50 Adding to Watch CoronaVirus List.
Wait Until Robinhood Traders Find Out...
Let’s be ‘Corona Clever’ and Catch one Before the POP. Athersys (ATHX) $1.85
It's a bit of a stretch...
Okay, it's a bit of a stretch,...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
Where is Citius Pharma (CTXR) in the FDA Approval Process?
We have a number of subscribers asking for an update on the FDA approval process for Mino-Lok. In layman's term (assuming approval)...
European Hand Sanitizer Market Expected to Reach $9.4 Billion by 2027.
Growing at a CAGR of 38.4% during 2019–2027.
The European hand sanitizer market was valued at US$ 641.7 million...
Antibiotic-Resistant Super Gonorrhea (CDC).
"We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common...
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
Starts at 1 Hour Mark.
INSIDER HOLDINGS
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...